The focus of this session will be the use of expression systems to significantly accelerate development and eventual commercialization of protein therapeutics. Talks might include discussion of current use (or potential use) of novel expression systems for this purpose, or the use of conventional expression systems in a different manner to achieve acceleration.
- Tim Charlebois, Pfizer
- Thomas Ryll, Biogen Idec
- Arvia Morris, Amgen: Efficient upstream process development programs generated using early molecule assessment and culture of continuous improvement
- Amy Shen, Genentech: Past and Present Strategies, Challenges, and Benefits of Stable Cell Line Development at Genentech
- Martin Allen, Pfizer: Streamlining the Discovery to Development Transition
- Rashmi Kshirsagar: Integration of Cell Culture Process Platform and Cell Line Expression Systems to accelerate Biopharmaceutical Development